Hayao Miyazaki’s net worth, biography, fact, career, awards and life story

Net Worth: $50 Million
Date of Birth: Jan 5, 1941 (79 years old)
Gender: Male
Height: 5 ft 4 in (1.64 m)
Profession: Film Director, Screenwriter, Film Producer, Animator, Writer, Animation Director, Mangaka, Illustrator, Author, Storyboard Artist
Nationality: Japan

Hayao Miyazaki Net Worth: Hayao Miyazaki is a Japanese film director, animator, artist, illustrator, producer, and screenwriter who has a net worth of $50 million. Hayao Miyazaki was born in Bunkyo, Tokyo, Japan in January 1941. He is an acclaimed maker of anime feature films. Hayao co-founded Studio Ghibli with Isao Takahata. He has been compared to Walt Disney, Nick Park, and Steven Spielberg. He started his career by joining Toei Animation in 1963. Hayao was an in-between artist for Gulliver’s Travels Beyond the Moon. His first feature film was 1979’s Lupin III: The Castle of Cagliostro. He had success with his 1984 film Nausicaa of the Valley of the Wind. Hayao was very popular in Japan but found worldwide success with 1997’s Princess Mononoke. The film became the first animated movie to win the Picture of the Year at the Japanese Academy Awards. His 2001 film Spirited Away won Picture of the Year again and was also the first anime film to win an American Academy Award. Princess Mononoke became the highest grossing film in Japan but was passed by Titanic. Titanic was then passed by Spirited Away in 2001. Hayao married Akemi Ota in 1965 and has two children. He has claimed he was retiring many times but said he was “quite serious” in late 2013.

You May Also Like

Patrick Soon-Shiong’s net worth, biography, fact, career, awards and life story

Patrick Soon-Shiong net worth: Patrick Soon-Shiong is a South African-born surgeon and drug developer who has a net worth of $15.5 billion dollars. Patrick Soon-Shiong is currently the richest person in Los Angeles thanks to an extremely lucrative career as a biotech entrepreneur. In 2010, Patrick purchased Magic Johnson’s 4.5% ownership stake in the Los Angeles Lakers. He is the largest Lakers owner outside of the Buss family. With the transaction, Soon-Shiong also acquired four courtside Lakers seats. Soon-Shiong was born to Chinese immigrants in South Africa on July 29, 1952. His parents fled China during World War II and settled in Port Elizabeth, South Africa. After graduating from high school at the age of 16, Patrick earned his medical degree from the University of the Witwatersrand in Johannesburg at the age of 23. He then earned a Master of Science from the University of British Columbia before moving to Los Angeles for surgical training. Soon-Shiong, who now holds over 50 patents, was a member of the UCLA Medical School faculty from 1983 to 1991. From Humble Surgeon to Multi-Billionaire Soon-Shiong left UCLA in 1991 and founded a biotechnology company called Abraxis BioScience. Under Patrick’s leadership, the company eventually developed a revolutionary drug used in the treatment of breast, lung and pancreatic cancers. The drug, Abraxane, was approved by the FDA in 2005 and the European equivalent in 2008 for the treatment of breast cancer when chemotherapy was not working. By 2009, Abraxane generated $315 million in revenue per year. In 2010 Abraxis BioScience, which was still solely owned by Soon-Shiong, was acquired by American biotech company Celgene for $3 billion in cash and stock. Turns out, this acquisition wasn’t even his biggest success in the business world! In 1997, Patrick founded a company called American Pharmaceutical Partners (APP) which manufactured generic intravenous medicines. By 2008, APP was generating $750 million per year in revenue, of which roughly $300 million was pure profit. In July of 2008, Homberg, Germany-based Fresnius SE agreed to acquire APP for $5.6 billion. At the time of the transaction, Patrick Soon-Shiong owned 80% of APP’s shares. Not one to rest on his laurels, Soon-Shiong founded another company called NantWorks in September 2011. Nantworks’s health division NantHealth aims to provide cloud-based data to the healthcare industry. One of the company’s super computers is now able to analyze and transfer the genetic data from a tumor in under a minute.
Read More